National and State-Specific Estimates of Settings of Receiving Human Papillomavirus Vaccination Among Adolescents in the United States

Overview

Journal J Adolesc Health

Publisher Elsevier

Specialty Pediatrics

Date 2021 Apr 19

PMID 33867229

Citations 3

Authors

Peng-Jun Lu

David Yankey

Benjamin Fredua

Mei-Chuan Hung

Tanja Y Walker

Lauri E Markowitz

Laurie D Elam-Evans

Affiliations

Soon will be listed here.

Abstract

Purpose: Human papillomavirus (HPV) vaccination in the United States has been recommended for girls since 2006 and for boys since 2011. However, settings of receiving HPV vaccination have not been assessed. The purpose of this study is to assess settings of receiving HPV vaccination among adolescents in order to understand what strategies are needed to improve vaccination uptake.

Methods: Data from the 2018 National Immunization Survey-Teen (NIS-Teen) were analyzed to assess place of HPV vaccination overall, and by gender, quarter, and other selected variables among adolescents in the United States. The 2016-2018 NIS-Teen data were combined to assess state-specific place of HPV vaccination.

Results: Among vaccinated adolescents aged 13-17 years, a doctor's office was the most common place where HPV vaccination was received (79.2%), followed by clinics, health centers, or other medical facilities (13.5%), health department (4.1%), hospital or emergency room (2.3%), schools (.5%), and pharmacies or stores (.4%). Overall, 99.1% of adolescents aged 13-17 years received HPV vaccination at medical settings and only .9% at nonmedical settings. Reported vaccination in nonmedical settings by state ranged from less than .1% in Delaware, Florida, and New Hampshire to 4.1% in North Dakota, with a median of 1.0%.

Conclusions: Doctor's offices were the most common medical setting for adolescents to receive HPV vaccination. Less than 1% of adolescents received vaccination at nonmedical settings. Continuing work with medical and nonmedical settings to identify and implement appropriate strategies are needed to improve HPV vaccination coverage among adolescents.

Citing Articles

HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US.

Saxena K, Kathe N, Sardana P, Yao L, Chen Y, Brewer N Hum Vaccin Immunother. 2023; 19(1):2161253.

PMID: 36631995 PMC: 9980633. DOI: 10.1080/21645515.2022.2161253.

HPV vaccination and factors influencing vaccine uptake among people of Indian ancestry living in the United States.

Ratnasamy P, Chagpar A Epidemiol Infect. 2022; 150:e152.

PMID: 35894243 PMC: 9428900. DOI: 10.1017/S0950268822001315.

Trends in adolescent COVID-19 vaccination receipt and parental intent to vaccinate their adolescent children, United States, July to October, 2021.

Nguyen K, Nguyen K, Geddes M, Allen J, Corlin L Ann Med. 2022; 54(1):733-742.

PMID: 35238263 PMC: 8903754. DOI: 10.1080/07853890.2022.2045034.

References

Markowitz L, Dunne E, Saraiya M, Lawson H, Chesson H, Unger E . Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-2):1-24. View

Head K, Biederman E, Sturm L, Zimet G . A retrospective and prospective look at strategies to increase adolescent HPV vaccine uptake in the United States. Hum Vaccin Immunother. 2018; 14(7):1626-1635. PMC: 6067847. DOI: 10.1080/21645515.2018.1430539. View

Ernst M, Bergus G, Sorofman B . Patients' acceptance of traditional and nontraditional immunization providers. J Am Pharm Assoc (Wash). 2001; 41(1):53-9. DOI: 10.1016/s1086-5802(16)31205-0. View

Ventola C . Immunization in the United States: Recommendations, Barriers, and Measures to Improve Compliance: Part 1: Childhood Vaccinations. P T. 2016; 41(7):426-36. PMC: 4927017. View

Elam-Evans L, Yankey D, Jeyarajah J, Singleton J, Curtis R, MacNeil J . National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years--United States, 2013. MMWR Morb Mortal Wkly Rep. 2014; 63(29):625-33. PMC: 5779424. View

Stokley S, Freed G, Curtis R, Gordon L, Humiston S, Parnell T . Adolescent vaccination: recommendations from the National Vaccine Advisory Committee. Am J Prev Med. 2009; 36(3):278-9.e6. DOI: 10.1016/j.amepre.2008.10.015. View

DHeilly S, Blade M, Nichol K . Safety of influenza vaccinations administered in nontraditional settings. Vaccine. 2006; 24(18):4024-7. DOI: 10.1016/j.vaccine.2005.09.061. View

Deuson R, Hoekstra E, Sedjo R, Bakker G, Melinkovich P, Daeke D . The Denver school-based adolescent hepatitis B vaccination program: a cost analysis with risk simulation. Am J Public Health. 1999; 89(11):1722-7. PMC: 1508974. DOI: 10.2105/ajph.89.11.1722. View

Moss J, Reiter P, Truong Y, Rimer B, Brewer N . School Entry Requirements and Coverage of Nontargeted Adolescent Vaccines. Pediatrics. 2016; 138(6). PMC: 5127065. DOI: 10.1542/peds.2016-1414. View

10.

. Place of influenza vaccination among adults --- United States, 2010-11 influenza season. MMWR Morb Mortal Wkly Rep. 2011; 60(23):781-5. View

11.

Meites E, Kempe A, Markowitz L . Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2016; 65(49):1405-1408. DOI: 10.15585/mmwr.mm6549a5. View

12.

Walker T, Elam-Evans L, Yankey D, Markowitz L, Williams C, Fredua B . National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019; 68(33):718-723. PMC: 6705894. DOI: 10.15585/mmwr.mm6833a2. View

13.

Dingman D, Schmit C . Authority of Pharmacists to Administer Human Papillomavirus Vaccine: Alignment of State Laws With Age-Level Recommendations. Public Health Rep. 2017; 133(1):55-63. PMC: 5805097. DOI: 10.1177/0033354917742117. View

14.

Dorell C, Yankey D, Strasser S . Parent-reported reasons for nonreceipt of recommended adolescent vaccinations, national immunization survey: teen, 2009. Clin Pediatr (Phila). 2011; 50(12):1116-24. DOI: 10.1177/0009922811415104. View

15.

Nodulman J, Starling R, Kong A, Buller D, Wheeler C, Woodall W . Investigating stakeholder attitudes and opinions on school-based human papillomavirus vaccination programs. J Sch Health. 2015; 85(5):289-98. PMC: 4576450. DOI: 10.1111/josh.12253. View

16.

Bernstein H, Bocchini Jr J . Practical Approaches to Optimize Adolescent Immunization. Pediatrics. 2017; 139(3). DOI: 10.1542/peds.2016-4187. View

17.

. Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011; 60(50):1705-8. View

18.

Lu P, OHalloran A, Ding H, Williams W, Bridges C, Kennedy E . National and state-specific estimates of place of influenza vaccination among adult populations - United States, 2011-12 influenza season. Vaccine. 2014; 32(26):3198-204. PMC: 5824644. DOI: 10.1016/j.vaccine.2014.04.003. View

19.

Steyer T, Ragucci K, Pearson W, Mainous 3rd A . The role of pharmacists in the delivery of influenza vaccinations. Vaccine. 2004; 22(8):1001-6. DOI: 10.1016/j.vaccine.2003.08.045. View

20.

Shah P, Calo W, Marciniak M, Gilkey M, Brewer N . Support for Pharmacist-Provided HPV Vaccination: National Surveys of U.S. Physicians and Parents. Cancer Epidemiol Biomarkers Prev. 2018; 27(8):970-978. PMC: 6092750. DOI: 10.1158/1055-9965.EPI-18-0380. View